Conversely, an up-regulation on-treatment of tumor CD73 expression has been found in a subset of melanoma patients who, in most cases, had progressed after pembrolizumab therapy or MART-1 adoptive T cell transfer therapy, suggesting a possible mechanism of drug acquired resistance [42]. Here, NT5E is linked to neoplasm.